SERPING1 and acquired angioedema: For disease control, management of the underlying B-cell clone is pivotal in AAE: case series report rituximab-based regimens achieving biochemical normalization and sustained remission of angioedema where autoantibody-mediated C1-INH loss is suspected [9].